Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
In this cohort, several community‐wide social/environmental factors were associated with MCI.
Why it matters
This study found that several community-level social and environmental factors, such as neighborhood disadvantage and air pollution, were associated with mild cognitive impairment. These are cross-sectional associations and do not prove that changing these factors would prevent or treat Alzheimer's disease.
-
Choline alfoscerate, a cholinergic precursor with limited evidence of efficacy in dementia management, has been used for various cognitive impairments in Korea.
Why it matters
In this observational study, the association between long-term choline alfoscerate use and risk of progression events related to treatment failure was unclear. A significant decrease of nearly 20% in the risk of all-cause mortality was associated with choline alfoscerate exposure, and a slight reduction in progression regarding treatment failure was observed only during the early stages of diagnosis.
-
44/100
After its completion in 2028, the EARHLI trial should offer evidence on the effect of hearing treatment versus a health education control on cognitive performance, social engagement, and brain organization/connectivity in 55- to 75-year-old community-dwelling adults with early ARHL and amnestic mild cognitive impairment.
Why it matters
This is a protocol for a trial testing whether hearing treatment affects cognition in people with early age-related hearing loss and mild cognitive impairment. No results are available yet, so no conclusion can be drawn about preventing cognitive decline.
-
We found a dose‐dependent association between ADI and dementia The ADI may be a valuable tool for identifying high‐risk communities for dementia intervention.
Why it matters
Among 1,613,337 veterans, 208,909 (12.8%) developed dementia, and compared to the least disadvantaged neighborhood quintile, all other groups had an increased risk of developing dementia after adjustment for sex, race/ethnicity, and psychiatric and medical comorbidities. The study is about the association between neighborhood deprivation and dementia risk, not about treating, curing, or preventing Alzheimer's disease.
-
This study reveals significant differences in driving patterns between cognitively normal older adults and those with cognitive impairment.
Why it matters
This study used GPS data to compare real-world driving patterns in older adults with and without cognitive impairment, finding that those with impairment made fewer full-cycle trips. It does not test any treatment, cure or prevention, but may inform strategies to support safe driving.
-
Ten‐year Black‐White disparities in prison population are associated with cognitive decline among people racialized as Black starting one year later.
Why it matters
This study examined whether county-level Black-White incarceration differences were linked to cognitive function in older adults racialized as Black. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
These programs are considered beneficial nonpharmacological cognitive training interventions for middle-aged women at high risk of cognitive impairment.
Why it matters
In this 60-person trial, middle-aged women who did virtual reality cognitive training showed significant improvement in cognitive scores and reduced depression compared with controls. The participants were middle-aged women at risk of cognitive impairment rather than people with Alzheimer's disease, so it does not show that this training treats, cures or prevents Alzheimer's disease.
-
The study protocol is part of a project approved and funded by the European Commission Horizon 2020 (grant agreement number 875221).
Why it matters
This is a protocol for a trial of personalized integrated care for older people, focused on quality of life and empowerment rather than Alzheimer's disease treatment. No results are available yet.
-
In sub-populations such as diabetes mellitus type 2, proliferative diabetic retinopathy is an independent predictor of ischemic stroke.
Why it matters
This position paper calls for a predictive, preventive and personalised approach to stroke management, noting that cryptogenic strokes account for 15 to 40% of stroke incidence. It concerns stroke, not Alzheimer's disease treatment, cure or prevention.
-
Technology offers opportunities to support older adults with mild cognitive impairments to remain independent and socially connected, but is often not used.
Why it matters
This qualitative study identified factors affecting whether cognitively impaired older adults adopt and continue using technology, noting the importance of disease awareness and cognitive ability. It is about technology use, not about treating, curing, or preventing Alzheimer's disease.
-
Poor adherence to drug dosing schedule is responsible for ∼50% of hospitalization cases.
Why it matters
This review describes wearable and implantable devices for drug delivery in chronic diseases, noting that conditions like dementia can contribute to poor adherence to dosing schedules. It concerns drug delivery technology generally and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Cardiovascular risk factors and lifestyle factors are associated with an increased risk of cognitive decline and dementia in observational studies, and have been targeted by multidomain interventions.
Why it matters
Pooling data from two multidomain intervention trials with 4162 participants, there were no differences between intervention and control groups in global cognition, depression, or apathy. This means the multidomain interventions did not improve these outcomes.
-
To assess whether home health agencies incur significantly higher care delivery costs for patients with cognitive impairment across three timeframes relevant to home health payment policy.
Why it matters
Home health agencies had significantly higher care delivery costs for patients with cognitive impairment across 30, 60, and 120 days. This is about payment and costs, not about treating, curing, or preventing Alzheimer's disease.
-
44/100
Per-dyad mean cost savings at 12 months were $2 354 for those who received COPE with a mean difference-in-difference of -$6 667 versus HCBS alone (95% CI: -$15 473, $2 734; not statistically significant).
Why it matters
This cost-benefit analysis found that per-dyad mean cost savings at 12 months for those who received COPE were not statistically significant compared with HCBS alone. It concluded that COPE represents a potentially cost-saving dementia care service that could be financed through existing Connecticut HCBS.
-
Limited data suggest nursing home (NH) Alzheimer's special care units (ASCUs) may improve care and outcomes among residents with dementia.
Why it matters
This study found that nursing home Alzheimer's special care units varied by region and rurality, while neighborhood deprivation was not significantly associated with their presence. It describes where these units are located and does not test whether they improve outcomes.
-
The agreement between the two measures of dementia differed by age: in 2017, 79.2% of hospital claims for patients aged 66–74 had a diagnosis of dementia compared to older age categories that had dementia noted in over 85% of records.
Why it matters
This study found that agreement between nursing home and hospital records on dementia diagnosis improved over time but gaps by age and race persisted. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Amyotrophic lateral sclerosis (ALS) has long been considered to be a purely motor disorder.
Why it matters
This review describes cognitive and behavioral manifestations in amyotrophic lateral sclerosis, including frontotemporal dementia. It notes that ALS-FTSD patients have worse prognosis and shorter survival, but it is about ALS, not Alzheimer's disease treatment or prevention.
-
Five overarching themes derived from the interviews were as follows: (a) My life still has value and meaning, (b) I am my own unique individual, (c) I place my trust in other people, (d) The future worries me, and (e) I accept and embrace what life brings.
Why it matters
This qualitative study found that people with dementia expressed worries about decline but primarily demonstrated resilience and acceptance, and wished to be recognised as unique and worthy humans until the end of life. It concluded that people with dementia are capable and willing to discuss the future and end-of-life topics.
-
The thematic analysis revealed 3 major issues.
Why it matters
This mixed methods study recruited 7 clinicians and 12 older adults with mild cognitive impairment to test a web-based decision aid, with thematic analysis revealing 3 major issues. The study did not report any outcomes related to treating, curing, or preventing Alzheimer's disease.
-
Dementia experience and dementia burden differ dramatically along race-education lines.
Why it matters
This study estimated life expectancy with and without dementia by education and race, finding blacks live more years with dementia at each education level. It documents disparities in dementia burden and does not test any treatment, cure or prevention.
-
When analyzing multiple mobility metrics together, different combinations of mobility metrics are related to specific adverse health outcomes.
Why it matters
This study used a wearable sensor to measure mobility in 1249 older adults and examined which gait scores predicted health outcomes including Alzheimer's disease dementia. It found different combinations of gait scores were associated with outcomes, but this is about risk prediction, not treatment or cure.
-
Neurodegenerative processes of various types of dementia start years before symptoms, but the presence of a "neural reserve", which continuously feeds and supports neuroplastic mechanisms, helps the aging brain to preserve most of its functions within the "normality" frame.
Why it matters
This paper discusses neurophysiological techniques and artificial intelligence as potential biomarkers for screening people with mild cognitive impairment who are at risk of dementia. It is about early detection, not treatment, cure, or prevention.
-
Late-onset NPS, even in a mild form (mild behavioural impairment) were found to be associated with an increased risk of dementia, even in the absence of cognitive impairment.
Why it matters
This review found that neuropsychiatric symptoms such as depression, irritability, apathy and anxiety are common in people with mild cognitive impairment and are linked to later cognitive decline. Late-onset neuropsychiatric symptoms, even mild ones, were associated with increased dementia risk even without cognitive impairment, which may help identify people who need closer monitoring.
-
Our aim is to develop a machine learning (ML) model that can predict dementia in a general patient population from multiple health care institutions one year and three years prior to the onset of the disease without any additional monitoring or screening.
Why it matters
This study developed a machine learning model using routine electronic medical record data that predicted dementia within one year of onset with nearly 80% accuracy across multiple institutions. It is a pre-screening and prediction tool, not a treatment, cure or prevention.
-
Individual differences in working memory relate to performance differences in general cognitive ability.
Why it matters
Models built from whole-brain functional connectivity predicted working memory performance in new individuals, including older adults with mild cognitive impairment and Alzheimer's disease. This shows connectivity patterns relate to memory ability, but it is a prediction study and does not test any treatment or prevention.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Social disadvantage outweighs knowledge in dementia risk
- Impact of disease type and temporal trends on the proximity of palliative care initiation to death in older adults: a population-based study
- Digital Gaming Interventions in Psychiatry: Evidence, Applications and Challenges
- Telephone-based identification of mild cognitive impairment and dementia in a multicultural cohort
- Advance directives and physicians' orders in nursing home residents with dementia in Flanders, Belgium: prevalence and associated outcomes
- A Skill-Based multimodal intervention for dementia caregivers: impact on burden and anxiety
- Leisure time physical activity and dementia risk: a dose-response meta-analysis of prospective studies
- Donepezil for dementia due to Alzheimer's disease
- Dysphagia in the elderly: management and nutritional considerations
- Mental health of caregivers for people with dementia and cerebral palsy as a key determinant of caregiver burden: a multivariable analysis